Last updated: August 1, 2026
Empagliflozin remains the commercial growth driver because its evidence base extends across type 2 diabetes, heart failure and chronic kidney disease. Linagliptin is a mature DPP-4 inhibitor with cardiovascular safety data, low hypoglycemia risk and a renal-dose-free label, but its market position is under pressure from SGLT2 inhibitors and GLP-1 therapies. The fixed-dose combination, marketed as Glyxambi, has a narrower growth opportunity than either component alone.
Empagliflozin has the stronger clinical and commercial profile. Its principal risks are U.S. loss of core composition-patent protection, generic entry, pricing pressure and competition from dapagliflozin, semaglutide and other cardiorenal therapies. Linagliptin faces earlier and broader generic pressure in several markets.
What are empagliflozin and linagliptin used for?
Empagliflozin is an oral sodium-glucose cotransporter-2, or SGLT2, inhibitor. Linagliptin is an oral dipeptidyl peptidase-4, or DPP-4, inhibitor.
| Product |
Active ingredient |
Drug class |
Principal brands |
Main approved uses |
| Jardiance |
Empagliflozin |
SGLT2 inhibitor |
Jardiance, Synjardy, Glyxambi, Trijardy XR |
Type 2 diabetes, heart failure, chronic kidney disease and cardiovascular-risk reduction, depending on jurisdiction |
| Tradjenta |
Linagliptin |
DPP-4 inhibitor |
Tradjenta, Trajenta, Glyxambi, Jentadueto in some markets |
Type 2 diabetes |
| Glyxambi |
Empagliflozin plus linagliptin |
SGLT2/DPP-4 fixed-dose combination |
Glyxambi |
Glycemic control in adults with type 2 diabetes |
Empagliflozin reduces renal glucose reabsorption and produces glycosuria. Its clinical value now extends beyond glucose lowering. Linagliptin increases incretin activity and lowers glucose without requiring renal dose adjustment, which supports use in patients with chronic kidney disease.
The combination is pharmacologically complementary. Empagliflozin provides cardiorenal effects, while linagliptin contributes incremental glucose lowering without materially increasing hypoglycemia when used without insulin or a sulfonylurea.
What are the latest major empagliflozin clinical-trial results?
Empagliflozin has the broader outcome-trial record.
EMPA-REG OUTCOME
EMPA-REG OUTCOME randomized 7,020 adults with type 2 diabetes and established cardiovascular disease. Empagliflozin reduced the primary composite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke versus placebo. Cardiovascular death declined by 38%, and all-cause mortality declined by 32% in the reported analysis (Zinman et al., 2015).
The trial established the commercial differentiation of Jardiance from glucose-lowering drugs supported primarily by hemoglobin A1c data.
EMPEROR-Reduced and EMPEROR-Preserved
EMPEROR-Reduced evaluated patients with heart failure and reduced ejection fraction. Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure by 25%, driven mainly by fewer hospitalizations (Packer et al., 2020).
EMPEROR-Preserved studied heart failure with preserved ejection fraction. The primary composite of cardiovascular death or hospitalization for heart failure fell by 21%, again primarily through fewer hospitalizations (Anker et al., 2021).
These studies expanded empagliflozin’s addressable market beyond diabetes. The heart-failure indication also reduced dependence on diabetes prescribing volumes.
EMPA-KIDNEY
EMPA-KIDNEY enrolled 6,609 patients with chronic kidney disease, including many without diabetes. Empagliflozin reduced the risk of kidney-disease progression or cardiovascular death by 28% versus placebo (The EMPA-KIDNEY Collaborative Group, 2023).
The results support use across a broad chronic kidney disease population and strengthen the strategic position of empagliflozin against DPP-4 inhibitors, which do not have comparable renal-outcome evidence.
Ongoing and adjacent research
The principal development opportunity is expansion across cardiorenal disease, including earlier chronic kidney disease, heart failure phenotypes and populations with or without diabetes. Combination studies with GLP-1 receptor agonists are commercially relevant because clinicians increasingly use complementary metabolic and cardiorenal mechanisms.
The main safety issues remain genital mycotic infections, volume depletion, ketoacidosis risk in selected settings and temporary treatment interruption around major surgery or acute illness. These risks are reflected in FDA labeling (U.S. Food and Drug Administration, 2023a).
What are the latest major linagliptin clinical-trial results?
Linagliptin’s evidence base is strongest for cardiovascular safety and renal usability rather than cardiovascular risk reduction.
CARMELINA
CARMELINA enrolled 6,991 adults with type 2 diabetes and high cardiovascular and renal risk. Linagliptin was noninferior to placebo for the composite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke. The trial did not show a meaningful increase in hospitalization for heart failure (Rosenstock et al., 2019).
The study supported the use of linagliptin in patients with advanced kidney disease without dose adjustment.
CAROLINA
CAROLINA compared linagliptin with glimepiride in 6,033 adults with type 2 diabetes and elevated cardiovascular risk. Linagliptin was noninferior to glimepiride for major cardiovascular events and caused substantially less hypoglycemia and less weight gain (Rosenstock et al., 2019b).
CAROLINA supports linagliptin as a safer alternative to sulfonylureas, but it does not give linagliptin the outcome-based differentiation associated with empagliflozin or GLP-1 receptor agonists.
Glycemic-control studies
Linagliptin generally lowers hemoglobin A1c by approximately 0.5% to 0.8% as monotherapy or add-on treatment, depending on baseline glycemia and background therapy. Its advantages are oral administration, low intrinsic hypoglycemia risk and no renal dose adjustment. Its limitations include modest glucose-lowering potency, lack of weight loss and limited evidence for reducing heart failure, renal or atherosclerotic events.
How does the empagliflozin-linagliptin combination compare with competing drugs?
Glyxambi combines two oral agents but does not replicate the clinical positioning of Jardiance monotherapy in heart failure or chronic kidney disease.
| Attribute |
Empagliflozin |
Linagliptin |
Combination |
| Glucose lowering |
Moderate |
Modest |
Additive |
| Weight effect |
Weight reduction |
Weight neutral |
Weight reduction driven by empagliflozin |
| Hypoglycemia risk |
Low without insulin or sulfonylurea |
Low |
Low without insulin or sulfonylurea |
| Cardiovascular-outcome evidence |
Positive in selected populations |
Cardiovascular safety |
Combination outcome evidence is less extensive |
| Heart-failure evidence |
Strong |
No comparable benefit |
Driven mainly by empagliflozin |
| Kidney-outcome evidence |
Positive |
Renal safety, not a comparable renal benefit |
Driven mainly by empagliflozin |
| Renal dosing |
Depends on indication and eGFR |
No dose adjustment |
Label and indication dependent |
| Main competitors |
Dapagliflozin, canagliflozin, GLP-1 agents |
Sitagliptin, alogliptin, saxagliptin |
SGLT2/GLP-1 combinations and generic separate tablets |
For most patients requiring cardiorenal risk reduction, an SGLT2 inhibitor is clinically more differentiated than a DPP-4 inhibitor. For patients who need incremental glycemic control and prefer oral therapy, the combination can reduce pill burden. The fixed-dose product competes against separate generic or branded tablets, which limits pricing power.
What is the FDA regulatory status of empagliflozin and linagliptin?
The FDA approved Jardiance in 2014 for glycemic control in adults with type 2 diabetes. Subsequent approvals expanded its label to cardiovascular-risk reduction, heart failure and chronic kidney disease indications (U.S. Food and Drug Administration, 2023a).
The FDA approved Tradjenta in 2011 for adults with type 2 diabetes. Glyxambi received approval in 2015 as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes (U.S. Food and Drug Administration, 2023b).
The regulatory distinction is material:
- Jardiance has multiple disease-specific indications.
- Tradjenta remains primarily a glycemic-control product.
- Glyxambi is positioned as a diabetes combination product, not as an independently established heart-failure or kidney-disease therapy.
- The combination’s future label expansion would require outcome evidence specific to the fixed-dose product or reliance on the empagliflozin component’s established benefits.
What patents protect empagliflozin, linagliptin and Glyxambi?
The patent estate consists of compound, formulation, combination and method-of-use rights. Core compound patents are more important for generic-entry timing than later formulation patents because an ANDA challenger can often avoid nonessential formulation claims.
| Product or component |
Patent category |
Commercial significance |
| Empagliflozin |
Core compound patent |
Primary barrier to generic Jardiance |
| Empagliflozin |
Crystal form, composition and formulation patents |
Can complicate substitution and product design |
| Empagliflozin |
Heart-failure and kidney-disease methods of use |
Relevant to labeling and induced-infringement risk |
| Linagliptin |
Core compound patent |
Principal barrier to generic Tradjenta |
| Linagliptin |
Combination and formulation patents |
Relevant to Glyxambi and other fixed-dose products |
| Glyxambi |
Fixed-dose composition and treatment patents |
Protects the combination, but not necessarily each component separately |
Publicly reported U.S. patent records identify key empagliflozin and linagliptin composition patents with nominal terms extending into the second half of the 2020s. The commercial end date depends on patent-term adjustment, pediatric exclusivity, terminal disclaimers, and the specific Orange Book listing.
The relevant U.S. regulatory pathway is an ANDA with Paragraph IV certification. A first-filer may obtain 180 days of generic exclusivity if statutory conditions are met. A Paragraph IV notice can trigger a 30-month stay of FDA approval when the patent holder files an infringement action within the statutory period under the Hatch-Waxman framework (U.S. Food and Drug Administration, 2024).
When does empagliflozin lose exclusivity?
The principal U.S. commercial exposure for empagliflozin is expected around the mid-to-late 2020s, subject to the patent and pediatric-exclusivity periods attached to the challenged claims. Core Jardiance protection has been widely associated with an expiration date in 2025, while later patents and regulatory exclusivities can delay practical substitution for specific indications or formulations.
A generic launch is likely to occur in stages:
- An initial product may enter after resolution or expiry of the core composition patent.
- Additional litigation may affect combination products such as Synjardy, Glyxambi and Trijardy XR.
- Generic empagliflozin may initially target type 2 diabetes, while branded heart-failure and kidney-disease labeling remains commercially differentiated.
- Price erosion is likely to accelerate after multiple manufacturers launch.
Patent expiry does not guarantee immediate full substitution. Payer formulary rules, supply contracts, indication-specific labeling and physician familiarity can delay the revenue impact.
When does linagliptin lose exclusivity?
Linagliptin’s principal U.S. composition protection has generally been associated with expiration in the late 2020s, with the exact date varying by patent and pediatric extension. Generic pressure is already more advanced outside the United States because national patent terms, settlements and market-entry rules differ.
Linagliptin is exposed to a sharper price decline than empagliflozin because:
- DPP-4 inhibitors have several therapeutic substitutes.
- The class has limited outcome differentiation.
- Generic sitagliptin and other low-cost oral agents compete directly.
- Payers can substitute within class without losing a major cardiorenal benefit.
Glyxambi may retain some commercial protection after separate-component generic entry if valid combination patents remain enforceable. That protection is weaker when clinicians can prescribe the generic components separately.
Which companies are challenging empagliflozin and linagliptin?
Generic competition is expected from large manufacturers with established diabetes portfolios, including Teva, Mylan/Viatris, Sandoz, Sun Pharma, Dr. Reddy’s Laboratories, Zydus, Cipla and other regional suppliers. The exact U.S. applicant list depends on FDA Orange Book certifications and litigation filings.
The competitive threat differs by product:
- Empagliflozin faces competition from dapagliflozin and canagliflozin before generic substitution fully develops.
- Linagliptin faces sitagliptin, alogliptin, saxagliptin and low-cost sulfonylureas.
- Glyxambi competes with separate tablets, other fixed-dose diabetes products and GLP-1-based regimens.
Boehringer Ingelheim and Eli Lilly commercialized Jardiance through a long-standing alliance. Boehringer Ingelheim commercializes Tradjenta in the United States, while certain international rights and commercialization arrangements vary by territory. The alliance increases global execution capacity but does not eliminate patent-cycle exposure.
What is the market size and forecast for empagliflozin and linagliptin?
Jardiance is the larger commercial asset. Company disclosures have reported Jardiance net sales in the multibillion-dollar range, supported by expanded heart-failure and chronic-kidney-disease use. Tradjenta sales are materially smaller and have matured as the DPP-4 class has lost share to SGLT2 and GLP-1 therapies (Boehringer Ingelheim, 2024; Eli Lilly and Company, 2024).
Third-party market forecasts differ because some reports measure active-ingredient sales, while others include branded combinations or the entire SGLT2 and DPP-4 classes. A practical base-case projection is:
| Segment |
2024-2025 market position |
2030 base-case outlook |
| Empagliflozin global branded and generic market |
Large, growing through cardiorenal indications |
Revenue growth shifts from volume expansion to post-patent price erosion |
| Linagliptin global market |
Mature, stable to declining |
Low-single-digit decline or flat nominal sales, depending on generic timing |
| Empagliflozin plus linagliptin fixed-dose combinations |
Niche within oral diabetes therapy |
Limited growth; likely greater price pressure than Jardiance |
| Global SGLT2 inhibitor class |
High-growth metabolic and cardiorenal segment |
Continued expansion, led by heart failure and kidney disease |
| Global DPP-4 inhibitor class |
Mature diabetes segment |
Low growth or decline as GLP-1 and SGLT2 use expands |
The strongest revenue scenario for empagliflozin is continued growth in non-diabetic chronic kidney disease and heart failure before generic entry, followed by partial retention through indication breadth and brand loyalty. The downside scenario includes rapid generic substitution, aggressive contracting and loss of premium pricing across diabetes and cardiorenal indications.
For linagliptin, the upside is concentrated in older patients, chronic kidney disease patients requiring a simple oral regimen and markets where GLP-1 therapies remain inaccessible. The downside is substitution by generic DPP-4 agents and broader movement toward therapies with weight and cardiovascular benefits.
How strong is the patent estate for empagliflozin versus linagliptin?
Empagliflozin has the stronger commercial exclusivity profile because patent protection is reinforced by a broader clinical franchise. Even after core composition-patent expiry, the product may retain demand in heart failure and kidney disease if generic labeling, payer rules or physician adoption develop unevenly.
Linagliptin has a technically meaningful composition and formulation estate but weaker market protection. Its clinical value is concentrated in glycemic control and renal dosing convenience. Those benefits are easier for competing oral products to replicate.
| Factor |
Empagliflozin |
Linagliptin |
| Patent strength |
Moderate to strong before core expiry |
Moderate before core expiry |
| Clinical differentiation |
High |
Moderate |
| Formulation dependence |
Moderate |
Moderate |
| Method-of-use value |
High because of cardiorenal indications |
Lower |
| Generic substitution risk |
High after core expiry, but potentially gradual |
High and potentially rapid |
| Revenue resilience |
Stronger |
Weaker |
What patent litigation and settlement issues affect these products?
The principal litigation risk is Hatch-Waxman litigation following Paragraph IV certifications against Orange Book-listed patents. Disputes may involve:
- Invalidity or noninfringement of compound patents.
- Obviousness challenges to crystalline forms.
- Scope of fixed-dose combination claims.
- Method-of-use claims covering heart failure or kidney disease.
- Patent-term adjustment and pediatric exclusivity.
- Authorized-generic or delayed-entry settlement provisions.
A settlement can establish an agreed generic-entry date earlier than patent expiry while preserving branded commercialization until that date. The economic effect depends on whether the settlement permits one generic, several authorized generics or unrestricted multi-source entry.
What are the main manufacturing and intellectual-property barriers?
Empagliflozin and linagliptin are small-molecule products, so neither faces the biologic manufacturing barrier associated with biosimilars. Generic manufacturers must still demonstrate pharmaceutical equivalence, bioequivalence, impurity control, polymorph consistency and stable commercial supply.
The main technical barriers are:
- Reproducing the active pharmaceutical ingredient at scale.
- Controlling crystalline form and particle characteristics.
- Matching dissolution and stability specifications.
- Demonstrating bioequivalence for fixed-dose combinations.
- Managing separate patents for combination products and delivery formats.
- Maintaining supply of both active ingredients for Glyxambi.
Biosimilar risk is therefore not relevant in the regulatory sense. The competitive risk is generic-drug substitution, not biosimilar interchangeability.
What generic launch scenarios exist for empagliflozin and linagliptin?
Early limited-entry scenario
One or two approved generics enter after settlement or core-patent resolution. Price erosion is initially moderate, and Jardiance retains substantial share in heart failure and kidney disease.
Multi-source launch scenario
Several manufacturers enter within a short period. Pharmacy-benefit managers impose aggressive substitution, producing rapid price compression and declining branded volume.
Combination-product scenario
Generic empagliflozin and linagliptin are available separately before a fully substitutable Glyxambi generic reaches the market. Physicians prescribe the components independently, reducing the value of the branded fixed-dose combination.
Indication-segmented scenario
Generic manufacturers obtain diabetes-focused labeling first, while branded Jardiance retains greater share in newer cardiorenal indications. This scenario would delay, but not prevent, broader erosion.
Key Takeaways
- Empagliflozin has the stronger clinical evidence, patent value and revenue outlook.
- EMPA-REG OUTCOME, EMPEROR and EMPA-KIDNEY support use across cardiovascular, heart-failure and kidney-disease settings.
- Linagliptin’s main strengths are cardiovascular safety, low hypoglycemia risk and no renal dose adjustment.
- Glyxambi offers additive glucose lowering but has less independent outcome differentiation.
- Empagliflozin faces major U.S. generic-entry risk around the mid-to-late 2020s.
- Linagliptin faces mature-class pressure and potentially faster substitution once core protection ends.
- The products are small molecules, so generic competition, not biosimilar competition, is the relevant threat.
- Jardiance is likely to retain more post-expiry value than Tradjenta because of its broader cardiorenal indications.
- The principal commercial variables through 2030 are patent resolution, generic launch concentration, payer substitution and continued heart-failure and chronic-kidney-disease uptake.
FAQs
Is empagliflozin more clinically valuable than linagliptin?
Yes, for patients with heart failure or chronic kidney disease, empagliflozin has substantially stronger outcome evidence. Linagliptin remains useful for glycemic control when renal-dose simplicity and low hypoglycemia risk are priorities.
Does Glyxambi provide the same heart-failure benefit as Jardiance?
The heart-failure evidence is primarily attributable to empagliflozin. Glyxambi is approved for glycemic control, and its fixed-dose combination label should not be treated as equivalent to the dedicated Jardiance heart-failure evidence base.
Will generic empagliflozin reduce Jardiance revenue immediately?
Not necessarily. Revenue erosion will depend on the number of entrants, settlement terms, payer substitution, indication-specific labeling and the timing of generic versions for related combination products.
Can linagliptin be used without renal dose adjustment?
Yes. Linagliptin is generally administered at the same dose across renal-function categories, which is a principal differentiating characteristic within the DPP-4 class.
Are empagliflozin and linagliptin biologics?
No. Both are chemically synthesized small-molecule drugs. Their follow-on products are regulated as generics through ANDA or equivalent national pathways, not as biosimilars.
References
-
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner-La Rocca, H. P., Choi, D. J., Chopra, V., Chuquiure, E., Giannetti, N., Gomez-Mesa, J. E., Janssens, S., Januzzi, J. L., Gonzalez-Juanatey, J. R., Merkely, B., Östlund, O., Piña, I. L., Pocock, S. J., ... Zannad, F. (2021). Empagliflozin in heart failure with a preserved ejection fraction. New England Journal of Medicine, 385(16), 1451-1461.
-
Boehringer Ingelheim. (2024). Annual report 2023. Boehringer Ingelheim.
-
Eli Lilly and Company. (2024). Annual report 2023. Eli Lilly and Company.
-
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., Jamal, W., Kimura, K., Schnee, J., Zeller, C., Cotton, D., Bocchi, E., Böhm, M., Choi, D. J., Chopra, V., ... Zannad, F. (2020). Cardiovascular and renal outcomes with empagliflozin in heart failure. New England Journal of Medicine, 383(15), 1413-1424.
-
Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., McGuire, D. K., Alexander, J. H., Cooper, M. E., Wanner, C., Zinman, B., & CARMELINA Investigators. (2019). Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk. JAMA, 321(1), 69-79.
-
Rosenstock, J., Kahn, S. E., Johansen, O. E., Zinman, B., Espeland, M. A., Woerle, H. J., et al. (2019). Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in type 2 diabetes. JAMA, 322(12), 1159-1169.
-
The EMPA-KIDNEY Collaborative Group. (2023). Empagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 388(2), 117-127.
-
U.S. Food and Drug Administration. (2023a). Jardiance prescribing information. FDA.
-
U.S. Food and Drug Administration. (2023b). Glyxambi prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, 373(22), 2117-2128.
